A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer.

Trial Profile

A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Anastrozole; Exemestane; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 27 Oct 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.
    • 01 Aug 2017 Planned End Date changed from 1 Sep 2017 to 31 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top